Excelsior Biopharma Cash Flow Quality Index
Excelsior Biopharma cash flow quality index. Excelsior Biopharma (6496) has a Cash Flow Quality Index of -3.02x as of December 2023. Operating cash flow of NT$-25.78 Million is below net income of NT$8.54 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial flexibility index of Excelsior Biopharma to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Excelsior Biopharma (2017–2020)
Cash flow quality index of Excelsior Biopharma from 2017 to 2020. Historical Cash Flow Quality Index for Excelsior Biopharma across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 6496 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Excelsior Biopharma Cash Flow Quality Index by Year (2017–2020)
Excelsior Biopharma cash flow quality index by year from 2017 to 2020. Year-by-year earnings quality comparison for Excelsior Biopharma. For the full cash flow conversion analysis, see Excelsior Biopharma operating cash flow efficiency.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 11.50x | NT$520.81 Million | NT$45.30 Million | ▲ +581.0% |
| 2019 | -2.39x | NT$-169.74 Million | NT$71.01 Million | ▼ -517.8% |
| 2018 | 0.57x | NT$126.92 Million | NT$221.83 Million | ▼ -54.2% |
| 2017 | 1.25x | NT$349.47 Million | NT$279.68 Million | — |